Medically reviewed by Stella Bard, MD Psoriatic arthritis (PsA) is a chronic (long-term) condition that includes symptoms of ...

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic arthritis, as well as progression of structural damage, according to new phase 3 ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have ...